Market Research Logo

Global Human Insulin Market 2015-2019

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Product profiles
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Disease overview
    • Epidemiology
      • Table Diabetes prevalence rate in various countries (2000 and 2030)
  • Pipeline analysis
  • Introduction
    • Key market highlights
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global human insulin market 2014-2019 ($ Billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type of insulin
    • Fast-acting insulin
    • Intermediate-acting insulin
    • Long-acting insulin
  • Market segmentation by type of disease
    • Table Global human insulin market by type of disease 2014
  • Geographical segmentation
    • Table Global human insulin market segmentation by geography 2014
  • Market drivers
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2014
      • Table Novo Nordisk: Company strategy
      • Table Modern insulins: Drug sales 2010-2014 ($ millions)
      • Table NovoRapid/NovoLog: Drug sales 2010-2014 ($ millions)
      • Table Levemir: Drug sales 2010-2014 ($ millions)
      • Table NovoMix: Drug sales 2010-2014 ($ millions)
      • Table Human insulins: Drug sales 2010-2014 ($ millions)
      • Table Sanofi: Company strategy
      • Table Lantus: Drug sales 2010-2014 ($ millions)
      • Table Apidra: Drug sales 2010-2014 ($ millions)
      • Table Insuman: Drug sales 2010-2014 ($ millions)
      • Table Lilly: Company strategy
      • Table Humalog: Drug sales 2010-2014 ($ millions)
      • Table Humulin: Drug sales 2010-2014 ($ millions)
    • Other prominent vendors
  • Key vendor analysis
    • Lilly
    • Novo Nordisk
    • Sanofi
  • Appendix
    • List of abbreviation
  • Explore Technavio

Global Human Insulin Market 2015-2019

About diabetes

Insulin is a hormone produced by beta cells of the pancreas that plays a key role in the regulation of blood glucose levels. It controls the body systems and regulates the uptake of amino acids by body cells. It helps cells absorb glucose from the blood. In diabetics, cells stop responding to the insulin produced. As a result, glucose in the blood cannot be absorbed by the cells of the body. This condition damages body tissues over the period of time and causes disabling and life-threatening health complications such as diabetic nephropathy and diabetic retinopathy. In type 1 diabetes, the body does not produces sufficient insulin to regulate blood glucose level. Individuals with this type of diabetes need to take insulin daily. Patients with type 2 diabetes also need doses of insulin coupled with medication. Different types of insulin such as human insulin and insulin analogs are available as insulin replacement therapy.

Technavio's analysts forecast the global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes.

Technavio's report, Global Human Insulin Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report includes a discussion of the key vendors operating in this market.Key vendors

  • Eli Lilly
  • Novo Nordisk
  • Sanofi
Other prominent vendors
  • Biocon
  • Biodel
  • Biogenomics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Diamyd Medical
  • Diasome Pharmaceuticals
  • DiaVacs
  • Pfizer
  • Generex Biotechnology
  • Lexicon Pharmaceuticals
  • Macrogenics
  • Merck
  • Oramed Pharmaceuticals
  • Osiris Therapeutics
  • Thermalin Diabetes
  • Tolerion
  • Wockhardt
  • XOMA Corporation
Market driver
  • Increase in prevalence of diabetes
  • For a full, detailed list, view our report
Market challenge
  • Stringent regulatory environment
  • For a full, detailed list, view our report
Market trend
  • Increasing R&D for novel mechanisms
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Human Insulin Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Human Insulin Market: Lilly, Novo Nordisk and Sanofi

The other prominent vendors are: Biocon, Biodel, Biogenomics, Boehringer Ingelheim, Bristol-Myers Squibb, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Pfizer, Generex Biotechnology, Lexicon Pharmaceuticals,Macrogenics, Merck, Oramed Pharmaceuticals, Osiris Therapeutics, Thermalin Diabetes, Tolerion, Wockhardt and XOMA

Commenting on the report, an analyst from Technavio’s team said: “The key players in the market are extending their support to academic institutions for R&D of innovative products for diabetes care. For instance, Sanofi Diabetes collaborated with academic institutions such as Helmholtz Zentrum and Charite to support R&D in the diabetes care segment. The recent collaboration of Sanofi and Gubra to discover new targets for diabetes is based on the consortium between the University of Copenhagen, Gubra and Gentofte Hospital, which is partly funded by the Danish National Advanced Technology foundation. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharma companies, which is expected to support the growth of the market.”

According to the report, diabetes is managed by the administration of insulin on a lifelong basis. However, insulin-based therapies are incapable of controlling blood glucose levels completely and are often associated with undesirable effects such as nocturnal hypoglycemia. During the fasting stage, glucose utilization increases and free fatty acid utilization decreases in the muscle cells, leading to hypoglycemia. In addition, fat breakdown decreases and fat storage increases in the liver cells, leading to weight gain. Severe hypoglycemic events and weight gain often result in poor patient compliance. Administered insulin therapies have lesser activity in liver and more activity in the periphery as compared to that of endogenous insulin. Therefore, there is a need to develop insulin therapies with better efficacy and safety profile, which is in turn driving market growth.

Further, the report states that the global human insulin market is witnessing patent expiries for major brands.

Companies Mentioned

Lilly, Novo Nordisk, Sanofi, Biocon, Biodel, Biogenomics, Boehringer Ingelheim, Bristol-Myers Squibb, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Pfizer, Generex Biotechnology, Lexicon Pharmaceuticals,Macrogenics, Merck, Oramed Pharmaceuticals, Osiris Therapeutics, Thermalin Diabetes, Tolerion, Wockhardt, XOMA

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;